Form 4: Voyager Therapeutics Director Glenn Pierce Acquires 24,000 Stock Options

Director Glenn Pierce acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing with the SEC.

Summary

• Glenn Pierce, a director of Voyager Therapeutics, Inc., acquired 24,000 stock options on June 5, 2024.
• The options were granted under the company's 2015 Stock Option and Incentive Plan, as part of the director compensation policy.
• The exercise price of the options is $8.70.
• The options vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent on continued service as a director.
• The expiration date for the options is June 5, 2034.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain any information that would significantly impact investor sentiment positively or negatively. It's a neutral event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry. This aligns management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry.
• Companies like Biogen, Amgen, and Gilead Sciences also use stock options as part of their director compensation packages.
• The vesting schedule of one year or the next annual meeting is also fairly typical.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates